PPD Opens Offices in Manila, Philippines, and Bangalore, India
February 18 2010 - 4:22PM
Business Wire
PPD, Inc. (Nasdaq: PPDI) today announced the opening of offices
in Manila, Philippines, and Bangalore, India, expanding its Phase
II-IV clinical development services in response to growing client
demand in Asia Pacific. PPD will provide clinical management
services in key therapeutic areas from both locations.
The offices strengthen PPD’s full range of drug discovery and
development services and continue to position the company to
capitalize on the tremendous growth of the outsourcing market in
Asia Pacific. PPD recently expanded in this region through its
acquisitions of Excel, the market leader and one of the largest
contract research organizations in China, and BioDuro, a drug
discovery outsourcing company.
“With 90 million people living in the Philippines and more than
20 million in Manila, there is enthusiasm for local expansion and
involvement in clinical trials,” said Lesley Gerrard, director of
clinical management in PPD’s Melbourne, Australia, office. “The
recent opening of the Manila office demonstrates
PPD’s commitment to the growth and development of emerging
markets in Southeast Asia and to further exploration of the
opportunities that exist within this region.”
Denzel Benjamin, director of clinical management in PPD’s
Bangalore office, added, “India is expected to conduct nearly five
percent of global trials by 2010, and the opening of our Bangalore
office advances our plans for expansion in India. This office
provides us easy access to all of our sites across south
India, which means cost savings for our clients and greater
efficiencies for PPD.”
The Manila office is located at Units 8 and 9, Alpha Building,
UP-AyalaLand TechnoHub, Commonwealth Ave., Quezon City, Philippines
1121. The Bangalore office is at Pine Valley, Stylus Office,
Embassy Golf-Links Business Park, Bangalore, India, 560071. For
more information about PPD services provided from Manila, call +632
332 9818 and from Bangalore, call +91 80 4176 4567.
PPD is a leading global contract research organization,
celebrating 25 years of advancing drug development. We provide
discovery, development and post-approval services as well as
compound partnering programs. Our clients and partners include
pharmaceutical, biotechnology, medical device, academic and
government organizations. With offices in 40 countries and more
than 10,500 professionals worldwide, PPD applies innovative
technologies, therapeutic expertise and a commitment to quality to
help its clients and partners maximize returns on their R&D
investments and accelerate the delivery of safe and effective
therapeutics to patients. For more information, visit our Web site
at http://www.ppdi.com.
Except for historical information, all of the statements,
expectations and assumptions contained in this news release,
including expectations and assumptions about the opening of our new
offices and globalization strategy, are forward-looking statements
that involve a number of risks and uncertainties. Although PPD
attempts to be accurate in making these forward-looking statements,
it is possible that future circumstances might differ from the
assumptions on which such statements are based. In addition, other
important factors which could cause results to differ materially
include the following: risks associated with geographic expansion;
success in sales growth; loss of large contracts; increased
cancellation rates; economic conditions and outsourcing trends in
the pharmaceutical, biotechnology, medical device, academic and
government industry segments; competition within the outsourcing
industry; the ability to attract and retain key personnel; risks
associated with and dependence on collaborative relationships;
risks associated with the development and commercialization of
drugs, including earnings dilution and obtaining regulatory
approval; risks associated with acquisitions and investments, such
as integration and impairments; rapid technological advances that
make our products and services less competitive; risks that we may
not continue our dividend policy; and the other risk factors set
forth from time to time in the SEC filings for PPD, copies of which
are available free of charge upon request from the PPD investor
relations department.
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Sep 2023 to Sep 2024